CRDF (Cardiff Oncology) Accounts Payable: $5.48 Mil (As of Mar. 2026)


CRDF Cardiff Oncology Inc CRDF
49 GF Score
Price $1.29
GF Value $1.43
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cardiff Oncology Accounts Payable?

Cardiff Oncology CRDF -0.77% 49 Accounts Payable is $5.48 Mil as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 49/100 and a GF Value™ of $1.43 (Fairly Valued). The stock has 4 warning signs investors should review.

Cardiff Oncology's Accounts Payable for the quarter that ended in Mar. 2026 was $5.48 Mil.

Cardiff Oncology's quarterly Accounts Payable increased from Sep. 2025 ($2.44 Mil) to Dec. 2025 ($8.09 Mil) but then declined from Dec. 2025 ($8.09 Mil) to Mar. 2026 ($5.48 Mil).

Cardiff Oncology's annual Accounts Payable increased from Dec. 2023 ($1.97 Mil) to Dec. 2024 ($4.82 Mil) and increased from Dec. 2024 ($4.82 Mil) to Dec. 2025 ($8.09 Mil).

Cardiff Oncology Accounts Payable Related Terms

Cardiff Oncology Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Accounts Payable Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.44 1.96 1.97 4.82 8.09

Cardiff Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 6.01 2.44 8.09 5.48
CRDF
49GF Score
Cardiff Oncology Inc CRDF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $5.48 Mil mean?
Cardiff Oncology (CRDF) has a Accounts Payable of $5.48 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Accounts Payable too high?
Cardiff Oncology's current Accounts Payable is $5.48 Mil. Overall, Cardiff Oncology has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Accounts Payable compare to MAIA and TELO?
Cardiff Oncology's Accounts Payable of $5.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Accounts Payable is $5.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Fairly Valued. The stock's GF Value™ is $1.43, compared to a current price of $1.29 — trading 10.1% below its estimated fair value. The current Accounts Payable is $5.48 Mil. Cardiff Oncology's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Accounts Payable is $5.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.29 is trading 10.1% below its estimated GF Value™ of $1.43. GuruFocus considers Cardiff Oncology to be Fairly Valued.

Key valuation signals for CRDF:

  • Accounts Payable: $5.48 Mil
  • GF Value™: $1.43 vs. price of $1.29 (10.1% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
49GF Score

Get the complete analysis for CRDF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price
$1.43
GF Value